[Incretins: do they exert cardiovascular effects?].
The physiological effects of the incretin hormone glucagon-like peptide-(GLP-)1 have contributed to the important role that incretin-based therapies with GLP-1 analogs or dipeptidyl peptidase-(DPP-)4 inhibitors already play in type 2 diabetes treatment. This development is not only due to the glucose-dependent insulinotropic effect of GLP-1 as well as the positive effects on beta cell function and, probably, beta cell mass, but also to the beneficial effects on body weight.Lately, the data on positive cardiovascular effects of GLP-1 have been growing. In animal models, GLP-1 improves left ventricular function and diminishes myocardial defects in ischemia models. In clinical studies with GLP-1 analogs, a normalization of blood pressure was observed and some of the data from animal studies after myocardial infarction or after invasive cardiologic or cardiosurgical interventions were also found under clinical conditions in humans. Additionally, an improvement of cardiovascular surrogate parameters was observed with incretin-based therapies. This review gives an overview on the cardiovascular effects of GLP-1 and incretin-based therapies.
Gallwitz
Baptist
B
Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany. baptist.gallwitz@med.uni-tuebingen.de
D000818:Animals; D048909:Diabetes Complications / Q000378:metabolism*; D006331:Heart Diseases / Q000209:etiology* / Q000378:metabolism*; D006801:Humans; D054795:Incretins / Q000378:metabolism*; D008955:Models, Cardiovascular
D054795:Incretins
Diabetes Care. 2005 May;28(5):1083-91
15855571
Diabetologia. 1993 Aug;36(8):741-4
8405741
J Pharmacol Exp Ther. 2005 Jan;312(1):303-8
15356213
Curr Med Res Opin. 2008 Jan;24(1):275-86
18053320
Lancet. 2009 Jul 4;374(9683):39-47
19515413
IDrugs. 2008 Jul;11(7):497-501
18600596
Circ Res. 2007 Feb 16;100(3):299-301
17307968
Lancet. 2009 Feb 7;373(9662):473-81
18819705
Diabetes. 1999 Apr;48(4):839-47
10102702
Diabetes Care. 2004 Nov;27(11):2628-35
15504997
J Am Coll Cardiol. 2009 Feb 10;53(6):501-10
19195607
Acta Physiol Scand. 1997 Aug;160(4):413-22
9338524
JAMA. 2007 Jul 11;298(2):194-206
17622601
Am J Cardiol. 2007 Sep 1;100(5):824-9
17719327
Diabetologia. 2009 Oct;52(10):2046-55
19688338
Endocrinology. 1996 Jul;137(7):2968-78
8770921
Am J Physiol. 1999 Nov;277(5):E784-91
10567003
Endocrinology. 2000 Dec;141(12):4600-5
11108273
J Clin Invest. 1993 Jan;91(1):301-7
8423228
Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E199-206
15271645
Diabetes Care. 2007 Jul;30(7):1901-3
17468349
Diabetes Metab. 2008 Feb;34 Suppl 2:S73-7
18640589
Endocrinology. 2003 Jun;144(6):2242-52
12746281
Regul Pept. 1999 Nov 30;85(1):9-24
10588446
Transplantation. 2007 Jan 15;83(1):24-8
17220786
Diabet Med. 2009 Mar;26(3):268-78
19317822
Curr Atheroscler Rep. 2009 Mar;11(2):93-9
19228481
Diabetes Obes Metab. 2006 Jul;8(4):436-47
16776751
J Med Chem. 2000 May 4;43(9):1664-9
10794683
Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15
15353407
Diabetes Obes Metab. 2009 Dec;11(12):1163-72
19930006
Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E701-7
12773303
J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13
16489128
Diabetes. 2000 May;49(5):741-8
10905482
Circulation. 2007 Mar 27;115(12):1544-50
17353438
Diabetes Care. 2009 Jan;32(1):84-90
18931095
Curr Med Res Opin. 2008 Oct;24(10):2943-52
18786299
Horm Metab Res. 2001 Feb;33(2):73-7
11294496
Lancet. 2002 Mar 9;359(9309):824-30
11897280
Diabetes Care. 2008 Aug;31(8):1582-4
18458146
Diabet Med. 2008 Sep;25(9):1129-31
19183322
Lancet. 2006 Nov 11;368(9548):1696-705
17098089
Diabetes Care. 2006 Dec;29(12):2632-7
17130196
Diabetes. 2000 Jun;49(6):883-8
10866038
J Endocrinol. 2009 Apr;201(1):59-66
19136619
Am J Physiol. 1997 Nov;273(5):E981-8
9374685
Regul Pept. 2008 Feb 7;146(1-3):243-9
17976835
Am J Med. 2009 Jun;122(6 Suppl):S11-24
19464424
N Engl J Med. 2001 May 3;344(18):1343-50
11333990
Diabetes. 1995 Dec;44(12):1433-7
7589851
J Clin Endocrinol Metab. 2004 Jun;89(6):2704-10
15181045
Circulation. 2004 Aug 24;110(8):955-61
15313949
Circulation. 2004 Mar 2;109(8):962-5
14981009
J Endocrinol. 2008 Jan;196(1):57-65
18180317
Diabetes Care. 2005 May;28(5):1092-100
15855572
Curr Opin Pharmacol. 2004 Dec;4(6):589-96
15525549
Diabetes. 2008 Oct;57(10):2577-87
18633100
Auton Neurosci. 2004 Jan 30;110(1):36-43
14766323
Curr Diabetes Rev. 2008 May;4(2):101-9
18473757
Diabetologia. 2002 Feb;45(2):195-202
11935150
Horm Metab Res. 2006 Dec;38(12):838-44
17163361
Acta Physiol Scand. 1996 Jul;157(3):355-7
8830893
Clin Ther. 2007 Jan;29(1):139-53
17379054
Endocrinology. 2003 Dec;144(12):5149-58
12960095
Gastroenterology. 2007 May;132(6):2131-57
17498508
Circulation. 2008 May 6;117(18):2340-50
18427132
Diabetes Care. 2007 Jun;30(6):1608-10
17372153
Diabetes. 2008 Aug;57(8):2046-54
18487451
Diabetes. 2009 Apr;58(4):975-83
19151200
Am J Cardiol. 2008 Sep 1;102(5):646-7
18721530
Diabetes Care. 2009 Jul;32(7):1224-30
19289857
Peptides. 1992 Jan-Feb;13(1):13-6
1320261
Diabetes Care. 1998 May;21(5):695-700
9589226
Diabetes. 2005 Jan;54(1):146-51
15616022
Clin Endocrinol (Oxf). 2009 Mar;70(3):343-53
18771570
Regul Pept. 2005 Feb 15;125(1-3):173-7
15582729
J Clin Endocrinol Metab. 1995 Mar;80(3):952-7
7883856
J Biol Chem. 1992 Apr 15;267(11):7402-5
1313797
Prim Care. 2006 Dec;33(4):887-901
17169672
Diabetes. 2009 Aug;58(8):1816-25
19401425
J Clin Invest. 2002 Jul;110(1):43-52
12093887
Am J Med. 2009 Jun;122(6 Suppl):S3-S10
19464426